Dynavax Technologies Corp (NASDAQ:DVAX)

CAPS Rating: 3 out of 5

A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.

Recs

0
Player Avatar uberpaige (56.97) Submitted: 2/26/2007 2:12:23 PM : Outperform Start Price: $5.20 DVAX Score: -26.72

another hope for quick accuracy points.

Featured Broker Partners


Advertisement